Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1Myeloid 1

Conditions

Lymphoma 2Leukemia 2Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1

Interventions

Rituximab 66Cyclophosphamide 52fludarabine phosphate 26fludarabine 22Filgrastim 21Vincristine 19Methotrexate 19Melphalan 19Doxorubicin 18Radiotherapy 17Etoposide 17Prednisone 16Tacrolimus 15Whole-Body Irradiation 14Mycophenolic Acid 14Cytarabine 14Peripheral Blood Stem Cell Transplantation 13Gemcitabine 13Cyclosporine 13Antilymphocyte Serum 13Lenalidomide 12Busulfan 11Bortezomib 11Granulocyte Colony-Stimulating Factor 9Alemtuzumab 9sargramostim 8Dexamethasone 8Cord Blood Stem Cell Transplantation 8pembrolizumab 7ibritumomab tiuxetan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Lymphoma × siplizumab × Clear all
NCT00113646 2018-03-16

Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies

Massachusetts General Hospital

Phase 2 Terminated
14 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes

NCT00105313 2007-06-14

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

MedImmune LLC

Phase 1 Terminated
80 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡